GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (WBO:GILD) » Definitions » Cyclically Adjusted PS Ratio

Gilead Sciences (WBO:GILD) Cyclically Adjusted PS Ratio : 2.89 (As of Apr. 27, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Gilead Sciences Cyclically Adjusted PS Ratio?

As of today (2024-04-27), Gilead Sciences's current share price is €61.42. Gilead Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was €21.22. Gilead Sciences's Cyclically Adjusted PS Ratio for today is 2.89.

The historical rank and industry rank for Gilead Sciences's Cyclically Adjusted PS Ratio or its related term are showing as below:

WBO:GILD' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.8   Med: 5.64   Max: 24.58
Current: 2.8

During the past years, Gilead Sciences's highest Cyclically Adjusted PS Ratio was 24.58. The lowest was 2.80. And the median was 5.64.

WBO:GILD's Cyclically Adjusted PS Ratio is ranked worse than
61.28% of 736 companies
in the Drug Manufacturers industry
Industry Median: 2.06 vs WBO:GILD: 2.80

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Gilead Sciences's adjusted revenue per share data for the three months ended in Dec. 2023 was €5.198. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €21.22 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Gilead Sciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Gilead Sciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Cyclically Adjusted PS Ratio Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.48 3.62 3.86 4.01 3.46

Gilead Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.01 3.76 3.41 3.24 3.46

Competitive Comparison of Gilead Sciences's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Gilead Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Cyclically Adjusted PS Ratio falls into.



Gilead Sciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Gilead Sciences's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=61.42/21.22
=2.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Gilead Sciences's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=5.198/129.4194*129.4194
=5.198

Current CPI (Dec. 2023) = 129.4194.

Gilead Sciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 2.151 99.695 2.792
201406 2.890 100.560 3.719
201409 2.864 100.428 3.691
201412 3.703 99.070 4.837
201503 4.472 99.621 5.810
201506 4.770 100.684 6.131
201509 4.917 100.392 6.339
201512 5.312 99.792 6.889
201603 4.957 100.470 6.385
201606 5.107 101.688 6.500
201609 4.991 101.861 6.341
201612 5.237 101.863 6.654
201703 4.608 102.862 5.798
201706 4.826 103.349 6.043
201709 4.142 104.136 5.148
201712 3.811 104.011 4.742
201803 3.126 105.290 3.842
201806 3.696 106.317 4.499
201809 3.669 106.507 4.458
201812 3.940 105.998 4.811
201903 3.643 107.251 4.396
201906 3.940 108.070 4.718
201909 4.016 108.329 4.798
201912 4.153 108.420 4.957
202003 3.953 108.902 4.698
202006 3.639 108.767 4.330
202009 4.428 109.815 5.219
202012 4.762 109.897 5.608
202103 4.275 111.754 4.951
202106 4.095 114.631 4.623
202109 4.998 115.734 5.589
202112 5.080 117.630 5.589
202203 4.741 121.301 5.058
202206 4.700 125.017 4.866
202209 5.640 125.227 5.829
202212 5.514 125.222 5.699
202303 4.705 127.348 4.782
202306 4.842 128.729 4.868
202309 5.255 129.860 5.237
202312 5.198 129.419 5.198

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Gilead Sciences  (WBO:GILD) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Gilead Sciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences (WBO:GILD) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.